Literature DB >> 6165473

Pharmacokinetics of bleomycin after im administration in man.

M M Oken, S T Crooke, M K Elson, J E Strong, R B Shafer.   

Abstract

The pharmacokinetics of bleomycin were studied after im injection in patients with malignant lymphoma. Mean peak serum concentrations of 0.133, 0.326, and 0.587 milliunits/ml were obtained approximately 1 hour after injection of 2, 5, and 10 units/m2, respectively. The mean half-life was 155 minutes, with a range of 65--235 minutes. Thirty-three percent of the administered dose was recovered in the urine after 4 hours. The urinary excretion of bleomycin was 61% during the 24 hours after injection, with some variability that was not explained by differences in dose or creatinine clearance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6165473

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

Review 1.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

3.  A pharmacokinetic evaluation of IM administration of bleomycin oil suspension.

Authors:  M Davy; E Paus; G Lehne
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line.

Authors:  P J Hepburn; R T Oliver; P A Riley; B T Hill; J R Masters
Journal:  Urol Res       Date:  1985

5.  Effect of Bleomycin Hydrolase Gene Polymorphism on Late Pulmonary Complications of Treatment for Hodgkin Lymphoma.

Authors:  Ádám Jóna; Zsófia Miltényi; Szilárd Póliska; Bálint László Bálint; Árpád Illés
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

6.  Mesenchymal stem cells are sensitive to bleomycin treatment.

Authors:  Nils H Nicolay; Alexander Rühle; Ramon Lopez Perez; Thuy Trinh; Sonevisay Sisombath; Klaus-Josef Weber; Anthony D Ho; Jürgen Debus; Rainer Saffrich; Peter E Huber
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

7.  Pulmonary Toxicity of Hodgkin Lymphoma Treatment: A Prospective Single-Center Study.

Authors:  Adam Jona; Zsofia Miltenyi; Laszlo Pinczes; Patricia Kerek; Nora Bittner; Maria Szilasi; Sandor Barna; Arpad Illes
Journal:  J Hematol       Date:  2021-12-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.